Combined Effects of Sensorimotor Integration and Post-facilitation Stretch in Autism Spectrum Disorder

March 25, 2026 updated by: Riphah International University

Combined Effects of Sensorimotor Integration and Post-facilitation Stretch on Toe Walking and Foot Posture in Children With Autism Spectrum Disorder

To determine the effects of sensory motor integration and post facilitation stretch on toe walking and sensory processing behaviors using Foot Posture Index and Sensory Profile respectively.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Autism spectrum disorder (ASD) is a complex neurodevelopmental disease that involves communication, social interaction and language in different ways. The autism toe walker is affected by outside world contact refusal: touching the ground as little as possible, trying to avoid any contact. The pathological walking caused by myotendinous retraction of the sural muscles bilaterally, succeeding in transforming an equine "attitude" into structured clubfoot walking. Many therapy options have been described: no treatment, physical therapy or casting to stretch the gastrocnemius, soleus, and Achilles' tendon, surgical lengthening of the gastrocnemius, soleus and Achilles tendon, blocking plantar flexion.

Sensorimotor integration is the process by which motor behaviors and sensory system processing take place together, with motor actions being continuously guided by sensory information.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Islamabad, Punjab Province, Pakistan
        • Recruiting
        • Fauji Foundation Hospital
        • Contact:
        • Contact:
          • Momina Tahir, MSOMPT*
        • Principal Investigator:
          • Momina Tahir, MSOMPT*

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Children with diagnosed Mild Autism Spectrum Disorder
  • Presenting with toe walk as a prominent feature of Autism Spectrum Disorder (e.g., more than 50% of steps observed during a gait assessment). Toe walking should be entirely because of Achilles tightness.
  • Able to follow simple verbal commands.
  • Sufficient gross motor skills present.

Exclusion Criteria:

  • Toe walking due to neurological (e.g., cerebral palsy, spina bifida, peripheral neuropathy) or orthopedic disorders (e.g., clubfoot, leg length discrepancy > 1 cm, hip dysplasia, contractures not related to idiopathic toe walking) and other behavioral factors that could be the primary cause of toe walking will be excluded.
  • History of Achilles tendon surgery or lower limb surgery.
  • Current participation in another physical therapy intervention targeting gait or posture
  • Severe behavioral/sensory issues that would interfere with treatment sessions i.e. severe Autism Spectrum Disorder with Attention Deficit Hyperactivity Disorder as well as mental retardation.
  • Non-ambulatory children.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Post-Facilitation Stretch

Gastrocnemius and soleus stretch (standing and supine)

• Ankle dorsiflexion with resistance (manual or band-assisted)
Other: Post-Facilitation Stretch
Gastrocnemius and soleus stretch (standing and supine) Ankle dorsiflexion with resistance (manual or band-assisted)
Experimental: Sensorimotor integration and Post facilitation stretch
Sensorimotor integration is facilitated by positioning the child in a seated posture and instructing them to use both feet to retrieve toys from a water-filled bucket and transfer them to another container. Other sensory motor integration activities involve play dough, hand imprinting etc.
Other: Sensorimotor Integration and Post-Facilitation Stretch
Sensorimotor integration is facilitated by positioning the child in a seated posture and instructing them to use both feet to retrieve toys from a water-filled bucket and transfer them to another container. Other sensory motor integration activities involve play dough, hand imprinting etc.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Foot Posture Index (FPI-6)
Time Frame: 4 weeks

The Foot Posture Index (FPI) is a clinical tool used to assess and quantify the posture of the foot.

Each of the six criteria is scored on a scale, typically from -2 to +2, with negative scores indicating supination, positive scores indicating pronation, and zero representing a neutral position. The individual scores are then summed to provide a total FPI score, which can range from -12 (highly supinated) to +12 (highly pronated).
4 weeks
Universal Half Goniometer
Time Frame: 4 weeks
Goniometers are a type of instrument used for precisely measuring angles. Goniometers consist of a graduated semicircle or full-circle where the measurements of angles are read, and two arms that meet at the vertex at the center of the semicircle or circle.
4 weeks
Sensory Profile (Short Form)
Time Frame: 4 weeks
The Short Sensory Profile (SSP) is a caregiver questionnaire used to assess sensory processing patterns in children, particularly those with autism spectrum disorder (ASD). It helps identify how children respond to various sensory stimuli and how these responses might impact their daily lives. The SSP is a shortened version of the Sensory Profile, designed for children aged 3 to 10 years.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Maria khalid, MSOMPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 20, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 20, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/Momina Tahir/02288

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on Post-Facilitation Stretch

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings